{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:05:40Z","timestamp":1793711140201,"version":"4.6.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Congenital myasthenic syndromes (CMS) are rare, heterogeneous, and often treatable genetic disorders depending on the underlying molecular defect. We performed a detailed clinical evaluation of seven patients from five unrelated families. Exome sequencing was performed on five index patients. Clinically significant variants were identified in four CMS disease-causing genes: <jats:italic toggle=\"yes\">COLQ<\/jats:italic> (3\/7), <jats:italic toggle=\"yes\">CHRNE<\/jats:italic> (2\/7), <jats:italic toggle=\"yes\">DOK7<\/jats:italic> (1\/7), and <jats:italic toggle=\"yes\">RAPSN<\/jats:italic> (1\/7). We identified two novel variants, c.930_933delCATG in <jats:italic toggle=\"yes\">DOK7<\/jats:italic> and c.1016_1032\u2005+\u20052dup in <jats:italic toggle=\"yes\">CHRNE<\/jats:italic>. A common pathogenic variant, c.955-2A&gt;C, has been identified in <jats:italic toggle=\"yes\">COLQ<\/jats:italic>-related CMS patients. Homozygosity mapping of this <jats:italic toggle=\"yes\">COLQ<\/jats:italic> variant in patients from two unrelated families revealed that it was located in a common homozygous region of 3.2\u2009Mb on chromosome 3 and was likely to be inherited from a common ancestor. Patients with <jats:italic toggle=\"yes\">COLQ<\/jats:italic> variants had generalized muscle weakness, those with <jats:italic toggle=\"yes\">DOK7<\/jats:italic> and <jats:italic toggle=\"yes\">RAPSN<\/jats:italic> variants had limb-girdle weakness, and those with <jats:italic toggle=\"yes\">CHRNE<\/jats:italic> variants had predominant ocular weakness. Patients with <jats:italic toggle=\"yes\">COLQ<\/jats:italic> and <jats:italic toggle=\"yes\">DOK7<\/jats:italic> variants showed improvement with salbutamol and <jats:italic toggle=\"yes\">CHRNE<\/jats:italic> with pyridostigmine therapy. This study expands the mutational spectrum and adds a small but significant cohort of CMS patients from India. We also reviewed the literature to identify genetic subtypes of CMS in India.<\/jats:p>","DOI":"10.1097\/mcd.0000000000000465","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T15:03:34Z","timestamp":1693407814000},"page":"162-167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Delineation of molecular characteristics of congenital myasthenic syndromes in Indian families and review of literature"],"prefix":"10.1097","volume":"32","author":[{"given":"Shivani","family":"Mishra","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik Vijay","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"R1-20250524","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/humu.22130","article-title":"Congenital myasthenic syndromes: achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice: a study of 680 patients.","volume":"33","author":"Abicht","year":"2012","journal-title":"Hum Mutat"},{"key":"R2-20250524","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nmd.2016.11.014","article-title":"Congenital myasthenic syndrome in Israel: genetic and clinical characterization.","volume":"27","author":"Aharoni","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"R3-20250524","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nmd.2011.10.009","article-title":"Current status of the congenital myasthenic syndromes.","volume":"22","author":"Engel","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"R4-20250524","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/cge.12762","article-title":"A homozygous nonsense variant in IFT52 is associated with a human skeletal ciliopathy.","volume":"90","author":"Girisha","year":"2016","journal-title":"Clin Genet"},{"key":"R5-20250524","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.nmd.2015.10.013","article-title":"Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations.","volume":"26","author":"Natera-de Benito","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"R6-20250524","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.nmd.2017.08.003","article-title":"Molecular characterization of congenital myasthenic syndromes in Spain.","volume":"27","author":"Natera-de Benito","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"R7-20250524","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/CND.0000000000000160","article-title":"COLQ-related congenital myasthenic syndrome and response to salbutamol therapy.","volume":"18","author":"Padmanabha","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"R8-20250524","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/archdischild-2013-304788","article-title":"How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia.","volume":"99","author":"Parr","year":"2014","journal-title":"Arch Dis Child"},{"key":"R9-20250524","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/ijms19061677","article-title":"The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes.","volume":"19","author":"Rodriguez Cruz","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R10-20250524","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/CND.0000000000000222","article-title":"Congenital myasthenic syndrome: spectrum of mutations in an Indian cohort.","volume":"20","author":"Selvam","year":"2018","journal-title":"J Clin Neuromuscul Dis"},{"key":"R11-20250524","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/jhg.2017.35","article-title":"Homozygous p.(Glu87Lys) variant in ISCA1 is associated with a multiple mitochondrial dysfunctions syndrome.","volume":"62","author":"Shukla","year":"2017","journal-title":"J Hum Genet"},{"key":"R12-20250524","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1042\/ETLS20180100","article-title":"Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome.","volume":"3","author":"Thompson","year":"2019","journal-title":"Emerg Top Life Sci"},{"key":"R13-20250524","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/WCO.0000000000000736","article-title":"The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies.","volume":"32","author":"Vanhaesebrouck","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"R14-20250524","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jocn.2019.11.030","article-title":"Congenital myasthenic syndrome: ten years clinical experience from a quaternary care south-Indian hospital.","volume":"72","author":"Wadwekar","year":"2020","journal-title":"J Clin Neurosci"},{"key":"R15-20250524","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamaneurol.2013.5590","article-title":"Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome.","volume":"71","author":"Witting","year":"2014","journal-title":"JAMA Neurol"}],"container-title":["Clinical Dysmorphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCD.0000000000000465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T20:01:32Z","timestamp":1748116892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCD.0000000000000465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mcd.0000000000000465","relation":{},"ISSN":["0962-8827"],"issn-type":[{"value":"0962-8827","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,19]]}}}